Tesirine intermediate-2

$286$5,700

Products Details

Product Description

– Tesirine intermediate-2 is the intermediate of Tesirine (HY-128952). Tesirine (SG3249), a pyrrole benzodiazepine (PBD) dimer, is a DNA small channel crosslinker with strong cytotoxicity. Tesirine can be used to synthesize Antibody-Drug Conjugates (ADCs), the warhead component of the payload is SG3199 (HY-101161), which has strong anticancer cell activity.

Web ID

– HY-24144

Storage Temperature

– -20°C, 3 years (Powder)

Shipping

– Blue Ice

Molecular Formula

– C40H55N5O10Si

References

– [1]Howard, et al. Process for the preparation of intermediates useful for the synthesis of pyrrolobenzodiazepine dimers. World Intellectual Property Organization, WO2013053872 A1. 2013-04-18.|[2]Tiberghien AC, et al. Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload. ACS Med Chem Lett. 2016;7(11):983-987. Published 2016 May 24.

CAS Number

– 1430738-34-3

Molecular Weight

– 793.98

Compound Purity

– 98.82

SMILES

– CC(C)(C)[Si](C)(C)O[C@@H]1N(C2=CC(O)=C(OC)C=C2C(N3[C@@]1([H])CC(C)=C3)=O)C(OCC4=CC=C(C=C4)NC([C@H](C)NC([C@H](C(C)C)NC(OCC=C)=O)=O)=O)=O

Clinical Information

– No Development Reported

Research Area

– Cancer

Solubility

– 10 mM in DMSO

Target

– DNA Alkylator/Crosslinker

Pathway

– Cell Cycle/DNA Damage

Product type

– Reference compound

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=